Morgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $206
Morgan Stanley analyst Judah Frommer maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $201 to $206.
Read original at benzingaStocks · News reference
Belite Bio Announces Additional Secondary Endpoint Data From Phase 3 DRAGON Trial Of Tinlarebant In Stargardt Disease, Presented At ASRS 2026 In Montréal
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease type 1, having met the primary efficacy endpoint, reduction in lesion growthPresentation to include positive update on
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 20, 2026, 12:06 PM
- Checked
- Jul 20, 2026, 12:06 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Cantor Fitzgerald Maintains Overweight on Belite Bio, Raises Price Target to $270
Cantor Fitzgerald analyst Steve Seedhouse maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $266 to $270.
Read original at benzingaFull Transcript: Belite Bio Q2 2026 Earnings Call
Belite Bio (NASDAQ:BLTE) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For
Read original at benzingaBelite Bio Q2 Adj. EPS $(0.54) Beats $(0.79) Estimate
Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.79) by 31.65 percent. This is a 8 percent decrease over losses of $(0.50) per share from the same
Read original at benzinga